$96.3 Million is the total value of Knoll Capital Management, LLC's 37 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HOOK | HOOKIPA PHARMA | $3,398,709 | -30.0% | 5,517,385 | 0.0% | 3.53% | -40.1% | |
| VRNA | Verona Pharmasponsored ads | $3,260,000 | -22.9% | 200,000 | 0.0% | 3.38% | -34.0% | |
| GDX | Vaneck Gold Miners ETFgold miners etf | $2,471,683 | -10.6% | 91,850 | 0.0% | 2.57% | -23.5% | |
| SIL | Global X Silver Miners ETF 37954Y848global x silver | $2,143,830 | -8.0% | 89,700 | 0.0% | 2.22% | -21.3% | |
| ENTX | Entera Bio Ltd | $1,801,099 | -14.0% | 2,484,275 | 0.0% | 1.87% | -26.3% | |
| GDXJ | Vaneck Junior Gold Miners ETFjunior hold mine | $1,713,024 | -9.6% | 53,150 | 0.0% | 1.78% | -22.6% | |
| BAH | Booz Allen Hamilton HLDG CORcl a | $1,420,510 | -2.1% | 13,000 | 0.0% | 1.48% | -16.1% | |
| V | Visa | $1,115,548 | -3.1% | 4,850 | 0.0% | 1.16% | -17.0% | |
| TMO | Thermo Fischer Scientific Inc | $1,062,957 | -3.0% | 2,100 | 0.0% | 1.10% | -16.9% | |
| CVS | CVS Health Corp | $1,012,390 | +1.0% | 14,500 | 0.0% | 1.05% | -13.5% | |
| MO | Altria Group Inc | $954,535 | -7.2% | 22,700 | 0.0% | 0.99% | -20.5% | |
| NOC | Northrop Grumman Corp | $953,011 | -3.4% | 2,165 | 0.0% | 0.99% | -17.3% | |
| OR | OSISKO GOLD ROYALTIES LTD | $732,000 | -24.5% | 400,000 | 0.0% | 0.76% | -35.3% | |
| ORGS | Orgenesis, Inc. | $393,537 | -55.4% | 634,738 | 0.0% | 0.41% | -61.8% | |
| Omega Therapeutics Inc. | $371,971 | -61.6% | 173,010 | 0.0% | 0.39% | -67.1% | ||
| OCUP | Ocuphire Pharma Inc. | $335,000 | -22.8% | 100,000 | 0.0% | 0.35% | -33.8% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Aldeyra Therapeutics Inc | 35 | Q3 2023 | 31.6% |
| Corbus Pharmaceuticals HLDGS | 30 | Q3 2022 | 46.5% |
| Abeona Therapeutics Inc | 30 | Q3 2022 | 34.8% |
| Biohaven Pharmactl Hldg Co L | 26 | Q3 2023 | 79.6% |
| Entera Bio Ltd | 22 | Q3 2023 | 7.8% |
| Ampio Pharmaceuticals Inc. | 21 | Q2 2018 | 11.0% |
| Soligenix Inc. | 20 | Q3 2022 | 1.7% |
| Eiger Biopharmaceuticals Inc | 19 | Q3 2022 | 5.8% |
| Applied Therapeutics Inc | 18 | Q3 2023 | 19.7% |
| Alcobra Ltd | 18 | Q3 2017 | 6.5% |
View Knoll Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| HOOKIPA Pharma Inc. | June 20, 2023 | 5,517,385 | 6.8% |
| Applied Therapeutics Inc. | January 23, 2023 | 3,450,000 | 7.2% |
| Orgenesis Inc. | August 14, 2020 | 1,316,364 | 5.9% |
| Corbus Pharmaceuticals Holdings, Inc. | February 14, 2020 | 5,045,870 | 7.1% |
| ABEONA THERAPEUTICS INC. | February 14, 2018 | 2,359,767 | 5.0% |
| SOLIGENIX, INC. | November 13, 2017 | 870,000 | 9.9% |
| ABEONA THERAPEUTICS INC. | February 14, 2017 | 2,359,767 | 5.9% |
| ALCOBRA LTD. | February 14, 2017 | 1,205,498 | 4.4% |
| Ampio Pharmaceuticals, Inc. | February 14, 2017 | 2,738,322 | 4.8% |
| RITTER PHARMACEUTICALS INC | February 14, 2017 | 952,434 | 8.2% |
View Knoll Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-01-16 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-04 |
| 13F-HR | 2023-08-15 |
| SC 13G | 2023-06-20 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-23 |
| 13F-HR | 2022-11-14 |
View Knoll Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.